Risposta clinica e sopravvivenza nel carcinoma renale metastatico durante somministrazione sottocutanea di sola interleuchina-2

Translated title of the contribution: Clinical response and survival of metastatic renal cell carcinoma to subcutaneous immunotherapy with interleukin-2 alone

P. Lissoni, S. Barni, G. Tancini, M. Cazzaniga, F. Frigerio, M. Chilelli, E. Scardino, M. Andres, P. Favini, T. Meroni, F. Verwei, A. Baccalin, M. Sala, B. Frea, E. Kocjancic, F. Rocco

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Several clinical studies have demonstrated the efficacy of subcutaneous immunotherapy with IL-2 alone in metastatic renal cell carcinoma (RCC). In an attempt to better define the clinical parameters which may predict the efficacy of treatment, the present study shows the results obtained with subcutaneous IL-2 alone in 91 evaluable metastatic RCC patients. IL-2 was injected subcutaneously at 3 million IU twice/day for 5 days/week for 6 weeks, corresponding to one immunotherapeutic cycle. In nonprogressing patients, a second cycle was given after 28-day rest period. A complete response (CR) was achieved in 2/91 patients. Moreover, 19/91 patients had a partial response (PR). Therefore, objective response (OR) rate was 21/91 (23%) patients. Stable disease (SD) was achieved in 41 patients, while the remaining 29 patients had a progressive disease (PD). OR rate was significantly higher in patients with a long disease-free survival than in patients with synchronous metastases, in nephrectomized patients than in the non-nephrectomized ones, and in patients with high than in those with low PS. The survival obtained in patients with CR or PA was significantly longer with respect to that found in patients with SD or PD. The toxicity was substantially low in all patients. This study confirms that the subcutaneous immunotherapy with IL-2 alone is an effective and well tolerated therapy of metastatic RCC.

Original languageItalian
Pages (from-to)41-47
Number of pages7
JournalArchivio Italiano di Urologia e Andrologia
Volume69
Issue number1
Publication statusPublished - 1997

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interleukin-2
Survival
Disease-Free Survival

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Lissoni, P., Barni, S., Tancini, G., Cazzaniga, M., Frigerio, F., Chilelli, M., ... Rocco, F. (1997). Risposta clinica e sopravvivenza nel carcinoma renale metastatico durante somministrazione sottocutanea di sola interleuchina-2. Archivio Italiano di Urologia e Andrologia, 69(1), 41-47.

Risposta clinica e sopravvivenza nel carcinoma renale metastatico durante somministrazione sottocutanea di sola interleuchina-2. / Lissoni, P.; Barni, S.; Tancini, G.; Cazzaniga, M.; Frigerio, F.; Chilelli, M.; Scardino, E.; Andres, M.; Favini, P.; Meroni, T.; Verwei, F.; Baccalin, A.; Sala, M.; Frea, B.; Kocjancic, E.; Rocco, F.

In: Archivio Italiano di Urologia e Andrologia, Vol. 69, No. 1, 1997, p. 41-47.

Research output: Contribution to journalArticle

Lissoni, P, Barni, S, Tancini, G, Cazzaniga, M, Frigerio, F, Chilelli, M, Scardino, E, Andres, M, Favini, P, Meroni, T, Verwei, F, Baccalin, A, Sala, M, Frea, B, Kocjancic, E & Rocco, F 1997, 'Risposta clinica e sopravvivenza nel carcinoma renale metastatico durante somministrazione sottocutanea di sola interleuchina-2', Archivio Italiano di Urologia e Andrologia, vol. 69, no. 1, pp. 41-47.
Lissoni, P. ; Barni, S. ; Tancini, G. ; Cazzaniga, M. ; Frigerio, F. ; Chilelli, M. ; Scardino, E. ; Andres, M. ; Favini, P. ; Meroni, T. ; Verwei, F. ; Baccalin, A. ; Sala, M. ; Frea, B. ; Kocjancic, E. ; Rocco, F. / Risposta clinica e sopravvivenza nel carcinoma renale metastatico durante somministrazione sottocutanea di sola interleuchina-2. In: Archivio Italiano di Urologia e Andrologia. 1997 ; Vol. 69, No. 1. pp. 41-47.
@article{2ef29b42253d4a92954d9a802311c792,
title = "Risposta clinica e sopravvivenza nel carcinoma renale metastatico durante somministrazione sottocutanea di sola interleuchina-2",
abstract = "Several clinical studies have demonstrated the efficacy of subcutaneous immunotherapy with IL-2 alone in metastatic renal cell carcinoma (RCC). In an attempt to better define the clinical parameters which may predict the efficacy of treatment, the present study shows the results obtained with subcutaneous IL-2 alone in 91 evaluable metastatic RCC patients. IL-2 was injected subcutaneously at 3 million IU twice/day for 5 days/week for 6 weeks, corresponding to one immunotherapeutic cycle. In nonprogressing patients, a second cycle was given after 28-day rest period. A complete response (CR) was achieved in 2/91 patients. Moreover, 19/91 patients had a partial response (PR). Therefore, objective response (OR) rate was 21/91 (23{\%}) patients. Stable disease (SD) was achieved in 41 patients, while the remaining 29 patients had a progressive disease (PD). OR rate was significantly higher in patients with a long disease-free survival than in patients with synchronous metastases, in nephrectomized patients than in the non-nephrectomized ones, and in patients with high than in those with low PS. The survival obtained in patients with CR or PA was significantly longer with respect to that found in patients with SD or PD. The toxicity was substantially low in all patients. This study confirms that the subcutaneous immunotherapy with IL-2 alone is an effective and well tolerated therapy of metastatic RCC.",
keywords = "immunotherapy, interleukin-2, renal cell carcinoma",
author = "P. Lissoni and S. Barni and G. Tancini and M. Cazzaniga and F. Frigerio and M. Chilelli and E. Scardino and M. Andres and P. Favini and T. Meroni and F. Verwei and A. Baccalin and M. Sala and B. Frea and E. Kocjancic and F. Rocco",
year = "1997",
language = "Italian",
volume = "69",
pages = "41--47",
journal = "Archivio Italiano di Urologia Nefrologia Andrologia",
issn = "1120-8538",
publisher = "Edizioni Scripta Manent s.n.c.",
number = "1",

}

TY - JOUR

T1 - Risposta clinica e sopravvivenza nel carcinoma renale metastatico durante somministrazione sottocutanea di sola interleuchina-2

AU - Lissoni, P.

AU - Barni, S.

AU - Tancini, G.

AU - Cazzaniga, M.

AU - Frigerio, F.

AU - Chilelli, M.

AU - Scardino, E.

AU - Andres, M.

AU - Favini, P.

AU - Meroni, T.

AU - Verwei, F.

AU - Baccalin, A.

AU - Sala, M.

AU - Frea, B.

AU - Kocjancic, E.

AU - Rocco, F.

PY - 1997

Y1 - 1997

N2 - Several clinical studies have demonstrated the efficacy of subcutaneous immunotherapy with IL-2 alone in metastatic renal cell carcinoma (RCC). In an attempt to better define the clinical parameters which may predict the efficacy of treatment, the present study shows the results obtained with subcutaneous IL-2 alone in 91 evaluable metastatic RCC patients. IL-2 was injected subcutaneously at 3 million IU twice/day for 5 days/week for 6 weeks, corresponding to one immunotherapeutic cycle. In nonprogressing patients, a second cycle was given after 28-day rest period. A complete response (CR) was achieved in 2/91 patients. Moreover, 19/91 patients had a partial response (PR). Therefore, objective response (OR) rate was 21/91 (23%) patients. Stable disease (SD) was achieved in 41 patients, while the remaining 29 patients had a progressive disease (PD). OR rate was significantly higher in patients with a long disease-free survival than in patients with synchronous metastases, in nephrectomized patients than in the non-nephrectomized ones, and in patients with high than in those with low PS. The survival obtained in patients with CR or PA was significantly longer with respect to that found in patients with SD or PD. The toxicity was substantially low in all patients. This study confirms that the subcutaneous immunotherapy with IL-2 alone is an effective and well tolerated therapy of metastatic RCC.

AB - Several clinical studies have demonstrated the efficacy of subcutaneous immunotherapy with IL-2 alone in metastatic renal cell carcinoma (RCC). In an attempt to better define the clinical parameters which may predict the efficacy of treatment, the present study shows the results obtained with subcutaneous IL-2 alone in 91 evaluable metastatic RCC patients. IL-2 was injected subcutaneously at 3 million IU twice/day for 5 days/week for 6 weeks, corresponding to one immunotherapeutic cycle. In nonprogressing patients, a second cycle was given after 28-day rest period. A complete response (CR) was achieved in 2/91 patients. Moreover, 19/91 patients had a partial response (PR). Therefore, objective response (OR) rate was 21/91 (23%) patients. Stable disease (SD) was achieved in 41 patients, while the remaining 29 patients had a progressive disease (PD). OR rate was significantly higher in patients with a long disease-free survival than in patients with synchronous metastases, in nephrectomized patients than in the non-nephrectomized ones, and in patients with high than in those with low PS. The survival obtained in patients with CR or PA was significantly longer with respect to that found in patients with SD or PD. The toxicity was substantially low in all patients. This study confirms that the subcutaneous immunotherapy with IL-2 alone is an effective and well tolerated therapy of metastatic RCC.

KW - immunotherapy

KW - interleukin-2

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0030873096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030873096&partnerID=8YFLogxK

M3 - Articolo

VL - 69

SP - 41

EP - 47

JO - Archivio Italiano di Urologia Nefrologia Andrologia

JF - Archivio Italiano di Urologia Nefrologia Andrologia

SN - 1120-8538

IS - 1

ER -